Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PN 200 vs Naproxen for Gastric Ulcer Prevention
NCT00367211Phase 3Completed
- Sponsor
- Pozen
- Start
- Sep 2006
- Primary completion
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of naproxen + omeprazole in osteoarthritis (OA), rheumatoid arthritis (RA) and ankylosing spondylitis (AS) (2 arms), sponsored by Pozen. Primary endpoint: Incidence of Gastric Ulcers at 6 months. Started Sep 2006; status: completed.
02
Drugs
naproxen + omeprazole
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT00367211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00367211.